Global Pre-Clinical Imaging (In-VIVO) Systems Market Size By Type (Optical imaging systems, Nuclear imaging systems), By Application (Clinic, Hospital), By Region, And Segment Forecasts, 2023 to 2032

The Global Pre-Clinical Imaging (In-VIVO) Systems Market was valued at USD 920 million in 2023 and is projected to surpass USD 1.76 billion by 2031, expanding at a CAGR of 8.4% during the forecast period from 2023 to 2031. The market growth is driven by the rising focus on drug discovery and development, the growing prevalence of chronic diseases, and the increasing demand for non-invasive imaging technologies. Pre-clinical in-vivo imaging systems provide crucial insights into biological processes in animal models, enhancing the understanding of disease mechanisms, treatment responses, and pharmacokinetics, thereby accelerating the translational research pipeline.

Drivers:

1. Rising Investment in Drug Development: Pharmaceutical and biotechnology companies are increasingly investing in R&D, and pre-clinical imaging plays a vital role in screening therapeutic candidates. High-throughput and real-time imaging technologies improve efficiency in drug development workflows.

2. Advancements in Imaging Modalities: The continuous evolution of technologies such as PET, MRI, CT, and optical imaging has led to more precise, high-resolution, and multiplexed imaging, further fueling adoption in academic and commercial research.

3. Growth in Cancer and Neurological Research: The rising burden of cancer and neurodegenerative diseases globally is propelling demand for pre-clinical imaging tools that offer anatomical, functional, and molecular insights, essential for developing targeted therapies.

Restraints:

1. High Cost of Equipment and Maintenance: Sophisticated imaging platforms such as PET/MRI hybrids require substantial investment and maintenance, limiting their adoption in small-scale laboratories or underfunded academic settings.

2. Ethical and Regulatory Concerns: Animal welfare regulations and ethical concerns about animal testing can pose challenges for the extensive use of in-vivo imaging systems, especially in regions with strict compliance mandates.

Opportunity:

1. Expansion of Contract Research Organizations (CROs): The growth of CROs offering pre-clinical imaging services to pharmaceutical firms presents a lucrative opportunity. These services reduce overhead for companies lacking in-house imaging infrastructure.

2. Integration with AI and Machine Learning: AI-powered analytics are transforming the analysis of imaging data, offering automated quantification, pattern recognition, and predictive insights that improve experimental outcomes and efficiency.

Market by System Type Insights:

Based on system type, the Optical Imaging Systems segment held the largest market share in 2023. These systems are favored for their sensitivity, low operational cost, and suitability for high-throughput screening in oncology and infectious disease research. Meanwhile, the Multimodal Imaging Systems segment is expected to witness the highest CAGR, as hybrid systems offering combined PET/CT or MRI/optical capabilities gain traction for their comprehensive diagnostic potential.

Market by End-use Insights:

By end-use, the Pharmaceutical & Biotechnology Companies segment dominated in 2023, driven by their critical use of pre-clinical imaging in early-stage drug discovery and validation. The Academic & Research Institutions segment is projected to grow steadily, supported by government funding and research collaborations focusing on disease modeling and translational studies.

Market by Regional Insights:

Geographically, North America led the global pre-clinical imaging market in 2023, attributed to its strong presence of top-tier pharmaceutical companies, advanced research infrastructure, and increased funding for biomedical research. Asia-Pacific is anticipated to witness the fastest growth rate during the forecast period, driven by increasing R&D spending, emerging biotech clusters, and growing collaborations with CROs in countries like China, India, and South Korea.

Competitive Scenario:

Key players in the Global Pre-Clinical Imaging (In-VIVO) Systems Market include PerkinElmer Inc., Bruker Corporation, FUJIFILM Holdings Corporation, Mediso Ltd., MILabs B.V., LI-COR Biosciences, MR Solutions Ltd., Aspect Imaging, TriFoil Imaging, and VisualSonics Inc. These companies are focused on product innovation, strategic partnerships, and geographic expansion. For instance:

In 2023, Bruker introduced its next-gen multimodal imaging platform integrating high-resolution MRI and fluorescence imaging.

In 2024, PerkinElmer expanded its imaging capabilities with AI-driven analysis tools aimed at speeding up pre-clinical study workflows.

In 2025, Mediso announced the opening of a new production facility in Europe to meet the increasing demand for hybrid imaging systems.

Scope of Work – Global Pre-Clinical Imaging (In-VIVO) Systems Market

Report Metric Details

Market Size (2023) USD 920 million

Projected Market Size (2031) USD 1.76 billion

CAGR (2023-2031) 8.4%

Market Segments By System Type, By End-use, By Region

Growth Drivers Drug discovery acceleration, tech innovation

Opportunities AI integration, CRO collaborations

Key Market Developments:

July 2023: FUJIFILM launched a compact pre-clinical imaging scanner designed for smaller laboratories, expanding access to high-resolution imaging tools.

October 2024: MR Solutions Ltd. integrated deep learning algorithms into its MRI platforms to automate image analysis and improve reproducibility.

March 2025: LI-COR Biosciences formed a strategic alliance with a biotech company to co-develop targeted imaging agents for cancer therapy studies.

FAQs:

1) What is the current market size of the Global Pre-Clinical Imaging (In-VIVO) Systems Market?

The market was valued at USD 920 million in 2023.

2) What is the major growth driver of the Global Pre-Clinical Imaging (In-VIVO) Systems Market?

The market is primarily driven by increased investment in drug discovery and advancements in imaging technology.